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We have expressed and purified three soluble fragments of the human LRIG1-ECD (extracellular domain): the
LRIG1-LRR (leucine-rich repeat) domain, the LRIG1-3Ig (immunoglobulin-like) domain, and the LRIG1-LR-
R-1Ig fragment using baculovirus vectors in insect cells. The two LRIG1 domains crystallised so that we have
been able to determine the three-dimensional structures at 2.3 Å resolution. We developed a three-dimen-
sional structure for the LRIG1-ECD using homology modelling based on the LINGO-1 structure. The
LRIG1-LRR domain and the LRIG1-LRR-1Ig fragment are monomers in solution, whereas the LRIG1-3Ig
domain appears to be dimeric. We could not detect any binding of the LRIG1 domains or the LRIG1-LRR-1Ig
fragment to the EGF receptor (EGFR), either in solution using biosensor analysis or when the EGFR was
expressed on the cell surface. The FLAG-tagged LRIG1-LRR-1Ig fragment binds weakly to colon cancer cells
regardless of the presence of EGFRs. Similarly, neither the soluble LRIG1-LRR nor the LRIG1-3Ig domains
nor the full-length LRIG1 co-expressed in HEK293 cells inhibited ligand-stimulated activation of cell-surface
EGFR.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
LRR (leucine-rich repeat) proteins have been
reported to modulate receptor activity in tissue stem
cells [1–4]. LRIG1 was discovered in 1996 as an
LRR/immunoglobulin (Ig) domain membrane glyco-
protein that was upregulated when a mouse glial cell
line was treated with retinoic acid [5]. LRIG1 appears
to regulate the levels of ErbB family members [6] by
increasing the degradation of these receptors [7].
Mutations to the intracellular domain of LRIG1 reduce
its effects on EGFR degradation [7], and LRIG1 also
increases the degradation of an oncogenic form of
the EGFR(vIII), which is missing domain I and mostuthors. Published by Elsevier Ltd. This
.org/licenses/by-nc-nd/4.0/).of domain II [8]. Although it has been reported that
cell-surfaceEGFR is necessary for the anti-proliferative
action of the soluble ectodomain of LRIG1 [9], more
recent reports indicate that the soluble form of LRIG1
inhibits the proliferation of glioma cells irrespective of
the levels of the EGFR [10].
In the last decade, LRIG1 has been reported
to interact with many receptor tyrosine kinases,
GDNF/c-Ret [11], E-cadherin [12], JAK/STAT [13],
c-Met [14,15], and the EGFR family [7,9] signalling
systems. In some cases, LRIG1 is reported to reduce
receptor levels by increasing the rates of degradation
[7]; in other reports, LRIG1 appears to bind directly to
the receptor kinase (e.g., the EGFR) [9]. These results
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1935LRIG1: Structure and Function Analysissuggest that part of the action of LRIG1 on the EGFR
family may be indirect [16]. At present, the broad
specificity of action of LRIG1 and the reported
opposing activity of LRIG3 [17] are difficult to
understand.
The ectodomain of LRIG1 has two distinct regions,
the proposed 15 LRRs (residues 41–494) and three
Ig-like domains closer to the membrane (residues
494–781) [18]. We have produced three fragments
of the ECD (extracellular domain) of human LRIG1:
LRIG1-LRR, LRIG1-3Ig, and LRIG1-LRR-1Ig. Two
of these LRIG1 fragments crystallised so that we
were able to determine the detailed molecular
structures. Using homology modelling based on the
LINGO-1 structure [19], we have developed a
structure for the entire LRIG1-ECD.
We have attempted to measure the interaction
between the FLAG-tagged LRIG1-LRR-1Ig with
membrane-associated human EGFR on A431 cells
and SW480 colorectal cancer cells, but we could not
detect any binding. Indeed, FLAG-tagged LRIG1-LR-
R-1Ig appeared to bind more strongly to SW620
colorectal cancer cells that do not express the EGFR
[20] than to SW480 colorectal cancer cells that do
express the EGFR. High concentrations of LRIG1
ectodomain fragments and EGFR did not interact on a
gel-filtration column or on a biosensor surface. When
we expressed full-length FLAG-tagged LRIG1 on
A431 cells, we could extract and immunoprecipitate
both LRIG1 and the EGFR individually, but the
reciprocal immune precipitations did not detect any
interaction between the proteins.
Apart from some limited indirect data from LRIG1
knockout mice [2,3,21], most of the LRIG1:EGFR
interaction data reported in the literature are derived
from overexpression systems [7]. The profound
effects of LRIG1 on the expression levels of so
many tyrosine kinase receptors raise a doubt that
there is a specific, direct interaction between the
ECDs of the EGFR and LRIG1. It is important to
determine whether a correctly folded LRIG1 ectodo-
main interacts directly with the EGFR-ECD and/or
whether LRIG1 associates with the EGFR on the
cell surface. Despite some interesting proposals
on the roles of LRR proteins [2], in particular, the role
of LRIG1 as a negative modulator of EGFR family
activation [2,22], we suggest that the signalling,
stem cell biology, and physiology attributed to LRIG
family members in mammalian systems need to be
re-evaluated.Results
Crystal structure of LRIG1-LRR domain
In our initial experiments, we could not express
the native LRIG1-LRR domain (41–494) [23] in ourbaculovirus system; however, by mutating four
residues at the N-terminus of the human LRR domain
to the equivalent hydrophilic residues present in the
zebrafish LRIG1 homologue (UniProt E7EZ01), to
produce the analogue Pro42Ser43Arg44Ser69L-
RIG1-LRR, we obtained excellent expression in Hi5
insect cells (i.e., N3 mg/L). Although none of these
residues are conserved in either LRIG2† or LRIG3‡,
the crystal structure of the Pro42Ser43Arg44Ser69-L-
RIG1-LRR domain (coding sequences 41–494) could
be solved by molecular replacement using the atomic
coordinates of decorin [24] as a search model. The
coordinates were refined against data to 2.3 Å
resolution. Data collection and structure refinement
statistics for the LRIG1-LRR (residues 41–494) are
summarised in Table 1.
The structure of LRIG1-LRR is crescent shaped,
characteristic of other LRRprotein structures (Fig. 1a).
It contains 19 β-strands with 16 LRRs (numbered 1–
16). There are 15 complete LRRs [1–15], each with
23–27 residues, where 11 LRRs have the 24-residue
repeat [LxxLxLxxNxLxxLxxxx(Hφ)xx(Hφ)xx, where
Hφ is any hydrophobic amino acid residue]. LRR16
is only a partial repeat with a new pattern
LxxLxIxSxxFx, where Ser appears to replace Asn in
the consensus repeat (LxxLxLxxNxLxx). This Ser
points towards the interior of the protein. It is
interesting to note that although Asn residues are
usually less conserved in LRR protein structures [25],
these Asn are completely conserved in 15 of the 16
LRRs and adopt the same orientation in each repeat
(Fig. 1a). The 16 LRR repeats are capped at both
ends by cysteine-rich modules. The LRR-NT has two
disulfide bridges (Cys41-Cys47 and Cys45-Cys54)
that cross-link two anti-parallel β-strands (Fig. 1a).
This N-capping motif (CxxxCxCxxxxxxC) at the start
of the crescent is remarkably similar to that of decorin
[24] and other extracellular LRR proteins [26]. The
LRIG1-LRR-CT includes residues 444–490 with the
pattern CxCx21Cx20C and resembles similar motifs
in domain 2 of Slit2 [27], NgR [28], and the Netrin G
ligands [29]. In addition to a common long α-helix
(Cys446-Arg458) and the 310-helix at the C-terminus
(Pro484-Ser486), LRIG1 has an additional β-strand
(Val464-Thr467) that hydrogen bonds to the LRR16
repeat (Fig. 1a).
The five predicted N-glycosylation sites for the
crystallised LRIG1-LRR (Asn74, Asn150, Asn246,
Asn292, and Asn318) are all modified (Fig. 1b). The
N-glycan on Asn74 is located on the concave face
of LRIG1-LRR and the N-glycan on Asn292 is
positioned on the edge of the concave groove
towards the middle of the LRR. The presence of
glycans on the concave face of the LRIG1-LRR also
occurs in LINGO-1 [19] and would be expected to
interfere with ligand binding to the N-terminal region
of LRIG1. The other three glycosylated sites
(Asn150, Asn246, and Asn318) are all located on
one flank next to the concave face of LRIG1, leaving
Table 1. LRIG1-LRR and LRIG1-3Ig X-ray diffraction data
collection and refinement statistics.
LRIG1-LRR LRIG1-3Ig
Data collection and processing
Resolution (Å) 50–2.3 (2.39–2.3) 50–2.76 (2.91–2.76)
Wavelength (Å) 0.954 0.954
Space group P21 2121 P43 212
Unit cell dimensions (Å)
a 38.94 121.04
b 94.76 121.04
c 169.43 115.8
Unique reflections 28,430 (3003) 22,552 (3112)
Redundancy 7.1 (7.4) 9.4 (9.3)
Completeness (%) 99.8 (99.9) 98.3 (89.2)
CC(1/2) (%) [25] 99.7 (57.5) 99.8 (29.5)
Rmerge 13.3 (224.2) 16.7 (300)
Average I/σ(I) 9.21 (0.87) 11.68 (0.88)
Refinement
Reflections for
refinement/test
26,998/1387
(2.38–2.3)
21,374/1153 (2.88–
2.76)
R/Rfree (%) 20/25.48 (37.2/
42.1)
20.47/25.33 (39.49/
46.91)
rmsd angle (°) 0.76 0.870
rmsd bond (Å) 0.004 0.006
Mean B-factor (Å) 69.7 94.9
Non-hydrogen protein
atom
3527 2232
Sugar atom 84 14
Water molecules 34 18
Ramachandran plot (%)
Favoured region 94 95.1
Allowed region 5.8 4.9
Outlier region 0.2 0.0
Structural values in parentheses are for the last-resolution shell.
1936 LRIG1: Structure and Function Analysisthe other flank and convex surface of LRIG1-LRR
sugar free.
Crystal structure of the LRIG1-3Ig domain
The LRIG1-3Ig domain expressed well in the Hi5
baculovirus/insect cell system. Crystals were obtain-
ed in space group P43212, with one molecule in the
asymmetric unit and a high solvent content (78%).
The structure was determined by molecular replace-
ment (see Materials and Methods) and refined to
2.76 Å resolution. The data collection and structure
refinement statistics are summarised in Table 1. The
crystal structure reveals that all three Ig domains
belong to the I-type of the immunoglobulin super-
family (IgSF) [30], with the two anti-parallel β-sheets
showing ABED and A′GFCC′ topology (Fig. 2).
LRIG1-3Ig is a rod-shapedmoleculewith Ig1 curving
away by about 30° from the linear arrangement for
alignment of the Ig2-Ig3 domains (Fig. 2a). The
interdomain buried surface areas for the Ig domains
are 421 Å2 for Ig1-Ig2 and 432 Å2 for Ig2-Ig3. The
interface between Ig1 and Ig2 includes the side chains
of Asn596 andPhe569 of Ig1 and Val597, His625, and
Ser677 of Ig2 (Fig. 2b). The side chains form a networkof five hydrogen bonds across the Ig1-Ig2 contact
region. The detailed interactions of the Ig2-Ig3 contact
region also include four hydrogen bonds, including the
backbone carbonyl oxygen of Val689 and the ND2
atom of Asn719 in Ig3. The side chain of Leu690 in Ig2
makes close contact with the side chain of Leu769 in
Ig3 (Fig. 2c).
Although there is only one molecule in the
asymmetric unit, the LRIG1-3Ig fragment forms a
dimer in the crystal through a crystallographic 2-fold
axis. This dimer is consistent with gel-filtration
chromatography measurements on the soluble pro-
tein (data not shown). The dimer interface is com-
posed of two identical sites between the LRIG1-Ig1
and LRIG1-Ig2 domains and is predominantly hydro-
phobic in nature (Fig. 2d). The total surface area
buried is 2691 Å2 with a shape complementarity value
of 0.63, which is typical for protein–protein interfaces
for immunoglobulin dimers [31]. At this interface, the
side chains of Val546, Val548, Met556, and Tyr558 in
LRIG1-Ig1 insert into the pocket formed by residues
Trp632, Phe640, Met648, Val650, and Phe657 in
LRIG1-Ig2 (Fig. 2e). The phenyl ring of Phe545 in Ig1
makes close contact with residues Ala631, Asn633,
and Thr673 fromLRIG1-Ig2. In addition, the backbone
N and O atoms of Trp632 form hydrogen bonds with
the LRIG1-Ig1 backbone at Val546. In the crystal,
these hydrogen bonds prevent Trp632 forming a
further hydrogenbondwithAsp639, accounting for the
missing C′ strand in LRIG-Ig2.
The crystal structure reveals that all three Ig domains
belong to the I-type of the immunoglobulin superfamily
(IgSF) [30], with the two anti-parallel β-sheets showing
ABED and A′GFCC′ topology (Fig. 3). The LRIG1-Ig1
(D1, residues 494–596) has extended strands βD and
βE,whereas Ig2 (D2, residues 597–690) has amissing
strand βC′. The Ig1 domain of LRIG1 closely resem-
bles the Ig1 domain of Axl [26] (PDB entry 2C5D) with
an rmsd of 1.6 Å for 92 Cα atoms and yet there is only
16% amino sequence identity. In the crystal structure
of the Axl-Gas6 complex [32], the extended strand βD
of Axl-Ig interacts with the strand βB of the vitamin-K-
dependent protein Gas6. Structural superpositions
(Fig. 3) suggest that Ig2 and Ig3 of LRIG1 are more
similar to each other (rmsd = 1.3 Å for 87 Cα atoms,
31% amino acid sequence identity) than to Ig1
(Ig2 N Ig1, rmsd = 1.4 Å for 80 Cα atoms; Ig3 N Ig1,
rmsd = 1.5 Å for 82 Cα atoms).
Effect of LRIG1 on the activity of the EGFR
We investigated the interaction (both functionally
and physically) between LRIG1 and the EGFR and
whether the soluble fragment LRIG1-LRR or LRI-
G1-3Ig from the ECD inhibited phosphorylation or
signalling in a cell line that overexpresses the EGFR
and constitutively stimulates phosphorylation of
Erk1/2 (MAPK1/2). A431 cells express N106 EGFR
per cell [33]; thus, it is easy to detect auto-tyrosine-
Fig. 1. Crystal structure of LRIG1-LRR domain. (a) Ribbon diagram of LRR. LRR-NT and LRR-CT are coloured marine
and lime, respectively. The β-strands are coloured magenta; helixes are coloured cyan and loops are coloured salmon.
The disulfide bonds in both LRR-NT and LRR-CT and the 15 Asn residues in each LRR repeat are shown in wireframe
representation; (b) five NAG glycosylation sites on LRR surface are shown in wireframe representation: oxygen, red;
nitrogen, blue; and carbon, yellow.
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LRIG1-LRR nor the LRIG1-3Ig ECD fragments
inhibited the autophosphorylation of the EGFR nor
the phosphorylation of Erk1/2 (Fig. 4). To test
whether full-length, membrane-associated LRIG1
might be required to observe an effect on the
EGFR, we transfected the A431 cells with FLAG-
tagged, full-length, native LRIG1 and cultured the
cells for 48 h. Interaction between LRIG1 and EGFR
was measured by immunoprecipitation using anti-
FLAG M2 beads (Fig. 5). As expected, the FLAG-
tagged LRIG1 was detected on the Western blot
analysis of the anti-FLAG M2 immunoprecipitates,
but there was only a small amount of associated
EGFR (as detected by Mab806 [34]; Fig. 5). The
presence of FLAG-LRIG1 did not alter either the
level of EGFR or the level of tyrosine phosphoryla-
tion of the EGFR on A431 cells (Fig. 5). In case that
the high level of EGFR on A431 cells was interfering
with our ability to detect an interaction between the
EGFR and LRIG1, we repeated the experiments inHEK293 cells transfected with FLAG-Myc-tagged
LRIG1 and/or the full-length EGFR (Fig. 6). The
anti-Myc immunoprecipitation from LRIG1 trans-
fected cells contained detectable LRIG1 (detected
on the Western with the anti-FLAG antibody). The
cells transfected with FLAG-tagged EGFR also
expressed detectable levels of EGFR running
slightly slower than LRIG1 (Fig. 6); however, there
was no detectable FLAG-EGFR in the LRIG1
immunoprecipitates from the FLAG-Myc-tagged
LRIG1:FLAG-tagged EGFR double transfectants
(Fig. 6).
Staining of colon cancer cells with FLAG-tagged
LRIG1-LRR-1Ig
It has been reported that LRIG1 binds specifically
to cells overexpressing the EGFR [9]. We have
investigated using fluorescence microscopy the
binding of FLAG-tagged LRIG1-LRR-1Ig to two
colon cancer cell lines: one expressing the EGFR
Fig. 2. Crystal structure of LRIG1-3Ig. (a) Ribbon diagram of LRIG1-3Ig. Ig1 is coloured lime; Ig2, olive; and Ig3, pink;
the N-acetylglucosamine is shown as a wireframe representation and the atoms are coloured as follows: nitrogen, blue;
oxygen, red; carbon, olive. (b and c) Residues involved in the interdomain regions of the Ig1-Ig2 interface and Ig2-Ig3
interface, respectively: oxygen, red; nitrogen, blue; carbon, lime (Ig1), olive (Ig2), and pink (Ig3); hydrogen bonds are
depicted as black broken lines; (d) ribbon diagram of LRIG1-3Ig crystallographic dimer. Domains are coloured as in (a);
(e) the Ig1-Ig2 dimer interface: residues Phe545, Val546, Val548, Met556, and Tyr558 of one Ig1 are displayed against the
surface electrostatic potential of the Ig2 domain of the other chain: red is negatively charged and blue is positively charged.
1938 LRIG1: Structure and Function Analysis
Fig. 5. Limited interaction between full-length LRIG1 and
the EGFR on A431 cells. A431 cells were transfected with
FLAG-tagged LRIG1. Whole cell lysates (WCL) were
incubated with anti-FLAG M2-agarose beads. Bound
proteins and WCL were separated by SDS-PAGE, followed
byWestern blot analysis using mouse anti-phosphotyrosine
mAb 4G10 (top panel), mouse anti-EGFRmAb 806 (middle
panel), and anti-FLAG mAb 9H1 (bottom panel). Lanes 1
and 3: FLAG peptide elution from LRIG1-M2 beads; lanes 2
and 4: SDS elution from LRIG1-M2 beads. lane 5: WCL of
A431 cells transfected with LRIG1; lane 6: WCL of A431
cells transfected with LRIG1 after M2-agarose depletion;
lane 7: WCL of A431 cells transfected with control plasmid;
lane 8: WCL of A431 cells transfected with control plasmid
after M2-agarose depletion.
Fig. 3. Structural superposition of three individual Ig
domains. Domains are depicted as ribbons with the strands
labelled as follows: Ig1, lime; Ig2, olive; and Ig3, pink.
1939LRIG1: Structure and Function Analysis(SW480 cells) [20] and the other one documented to
lack the EGFR, SW620 cells [20,35]. As expected, in
our immunofluorescence assay, anti-EGFR antibody
detected EGFR on SW480 cells (Fig. 7a) but thereFig. 4. No inhibition of EGFR signalling in A431 cells by
LRIG1-LRR or LRIG1-3Ig. A431 cells were treated for 2 h
at 37 °C with either recombinant LRIG1-LRR or LRIG1-3Ig
at 0, 10, and 100 μg/mL, as indicated. Cells were lysed
as described in Materials and Methods. Protein extracts
were separated by SDS-PAGE, followed by Western
blot analysis using anti-phosphotyrosine antibody 4G10
(top panel) and anti-Erk1/2 antibody (bottom panel).was no staining associated with the SW620 cells
(Fig. 7a). Treatment of the SW480 cells with EGF led
to the downregulation (internalisation) of the EGFR
(see Fig. 7a and b). This downregulation was same
whether or not LRIG1-LRR-1Ig was present
(Fig. 7a). Treatment of the SW480 cells with
FLAG-tagged LRIG1-LRR-1Ig alone did not alter
the level of EGFR detected on the SW480 cells
(Fig. 7a). In contrast, the interaction of FLAG-tagged
LRIG1-LRR-1Ig to SW480 cells or SW620 cells was
not above background levels (Fig. 7b), indicating
that any low level interaction of LRIG1 with the cell
surface is independent of the level of expression of
the EGFR. Similar staining patterns were also
observed with the FLAG-tagged LRIG1-LRR domain
(data not shown).
Interaction between LRIG1-LRR and the EGFR
ECD
Even when mixed at high concentration
(N1 mg/mL for each protein), FLAG-tagged
LRIG1-LRRand a high-affinity formof the EGFR-ECD
(i.e., EGFR1–501-Fc) did not appear to interact (Fig. 8).
Gel-filtration analysis showed that, when themixture
was chromatographed on Superdex 200, both
proteins eluted at their expected positions and
that no LRIG1:EGFR complex could be detected
at higher molecular weights (Fig. 8, inset).
Fig. 6. No detectable interaction between full-length
LRIG1 and EGFR on HEK293T cells. Top panel: Western
blot analysis of LRIG1 immunoprecipitates (anti-Myc, mAb
9E10) from whole cell lysates (WCL) of HEK293T cells
transfected with the following: lane 1, FLAG-Myc-tagged
LRIG1; lane 2, FLAG-tagged EGFR (1 μg of cDNA); lane
3, FLAG-tagged EGFR (3 μg of cDNA); lane 4, FLAG-
Myc-tagged LRIG1 and FLAG-tagged EGFR (1 μg of each
cDNA); and lane 5, FLAG-Myc-tagged LRIG1 and FLAG-
tagged EGFR (3 μg each cDNA). Blots were developed
with the anti-FLAG mAb 9H1. Bottom panel: Western blot
analysis of WCL from HEK293T cells transfected with
the following: lane 1, FLAG-Myc-tagged LRIG1 (1 μg of
cDNA); lane 2, FLAG-tagged EGFR (1 μg of cDNA); lane
3, FLAG-tagged EGFR (3 μg of cDNA); lane 4, FLAG-
Myc-tagged LRIG1 and FLAG-tagged EGFR (with 1 μg of
each cDNA); and lane 5, FLAG-Myc-tagged LRIG1 and
FLAG-tagged EGFR (with 3 μg each cDNA). Blots were
developed with the anti-FLAG mAb 9H1.
1940 LRIG1: Structure and Function AnalysisSimilar experiments were repeated for the LRI-
G1-3Ig fragment (at 0.5 mg/mL) by mixing with the
EGFR1–501 or EGFR1–621 ECD. Again, no LRIG1-3Ig:
EGFR-ECD complex was detected by gel-filtration
chromatography.
If the interactions between EGFR and LRIG1
are low affinity, gel filtration can allow dissociation
of complexes. Consequently, we investigated the
interaction of an LRIG1-LRR-1Ig-ECD fragment and
EGF with two forms of immobilised EGFR-ECD. In
these experiments, either EGFR1–621 or EGFR1–501
was coupled to the biosensor chip and different
dilutions of either the LRIG1-LRR-1Ig-ECD fragment
(0.25–8 μM) or EGF (3–200 nM) were injected into
the fluid flowing over the chip (see Fig. 9). Both forms
of the EGFR interacted with the EGF (Fig. 9c and d);
as expected, EGFR1–621 had a low binding affinity for
EGF, whereas the EGFR1–501-Fc bound EGF tightly
[36]. In contrast, the LRIG1-LRR-1Ig-ECD fragment
failed to interact with either EGFR1–621 or EGFR1–501
(see Fig. 9a and b). These experiments were
repeated with the LRIG1-3Ig-ECD fragment (see
Supplementary Fig. 3a–d); again, EGF bound to the
receptor, but there was no detectable interaction with
either of the EGFR-ECD fragments even at the
highest concentration of this fragment (8 μM).Discussion
The crystallisation of full-length, glycosylated
ectodomains of cell-surface receptors can be prob-
lematic: often, there is variability in the glycosylation
and even the orientation of the subdomains can be
context dependent. LRRs fold into several canonical
forms producing flat surfaces capable of participat-
ing in protein–protein interactions [25]. As is the case
for LINGO-1 [19], both the concave and convex
surfaces of the LRIG1-LRR domain are flat, but the
concave surface is glycosylated, whereas the
convex surface is free of glycosylation. Both
structures have N-terminal caps and Ig-like domains
at the C-terminus. When the LINGO-1-LRR and
LRIG1 three-dimensional structures are aligned at
the C-terminal region, the N-terminal region of
LRIG1 diverges from the LINGO-1-LRR by 40 Å
(see Supplementary Fig. 2). The prominent bulge at
the C-terminus of the LINGO-1-LRR [19] is not as
prominent in the LRIG1-LRR; however, the conforma-
tion of the region linking the LRRand Ig-like domains is
similar in the two structures. The structural homology
between the LINGO-1-Ig1 and the LRIG1-Ig1 domains
suggests a model for the juxtaposition of the LRR
domain and the Ig-like domains in LRIG1, where
the LRR domain would be projected away from the
cell surface (Supplementary Fig. 1). Analysis of LRIG1
species homology does not reveal any strongly
conserved regions of the surface. The LRIG1-LRR:
LRIG1-LRR fragment interactions in the crystal lattice
occur between the terminal residues and do not
appear to occlude sufficient surface area to indicate
any physiological interaction sites.
Our attempts to detect an interaction between
the LRIG1 and the EGFR were not successful.
We tried measuring a direct interaction between
LRIG1-ECD fragments and two soluble forms of the
EGFR: EGFR1–621-ECD or the EGFR1–501 or the
EGFR1–501-Fc. All of the molecules were folded
correctly, but no interaction was detected by gel
filtration or biosensor analysis. The soluble LRI-
G1-ECD fragments bound weakly, if at all, to colon
cancer cell lines and the level of these interactions
was not influenced by the presence of EGFRs.
By transfecting full-length LRIG1 into HEK293
cells that were overexpressing members of the
EGFR family (EGFR, ErbB2, ErbB3, and ErbB4),
others have reported pull-down of LRIG1:EGFR,
LRIG1:ErbB2, LRIG1:ErbB3, and LRIG1:ErbB4
complexes [7]; effects of LRIG1 on cell proliferation;
and effects of LRIG1 on cell-surface EGFR levels,
autophosphorylation, and signalling. Surprisingly,
the EGFR pulled down full- length LRIG1,
ΔLRR-LRIG1, and ΔIg-LRIG1 but not ΔLRR-ΔIg-L-
RIG1; that is, the EGFR appeared to interact
significantly with both the LRR and 3Ig domains.
The intracellular domain of LRIG1 did not interact
with the EGFR [7]. However, LRIG1 can negatively
Fig. 7. Analysis of the interaction between FLAG-tagged LRIG1-LRR-1Ig with the SW480 (EGFR+) and SW620
(EGFR−) colon cancer cell lines. The cells were cultured in Ibidi chamber slides (5 × 103/well) for 3 days then stimulated
with or without EGF (100 ng/mL) at 37 °C for 15 min. The cells were incubated with or without FLAG-LRIG1-LRR-1Ig
(1 μM) at 4 °C for 45 min, and then with either the mouse antibody mAb528 (to detect the human EGFR) or the mouse
anti-FLAG tag M2 antibody (to detect the FLAG-LRIG1-LRR-1Ig). (a) Antibody binding was detected with Alexa
488-labelled anti-mouse Ig and the cells were counterstained with 4′,6-diamidino-2-phenylindole and phalloidin. (b) The
mean and relative fluorescence levels for the cells in three separate fields for each condition were quantitated as described
previously [55]. The results from two independent experiments (red and blue bars) are presented. FLAG-tagged
LRIG1-LRR-1Ig was abbreviated as LRR-1Ig.
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Fig. 7 (continued).
1942 LRIG1: Structure and Function Analysisregulate the oncogenic Δ2-7EGFR [8], which lacks
a significant portion of the EGFR ectodomain.
Our attempts to obtain similar evidence for an
LRIG1-EGFR interaction on the surface of A431 or
HEK293 cells were unsuccessful. There were no
significant levels of the EGFR in the LRIG1 pull--Fig. 8. Gel-filtration analysis of FLAG-tagged LRIG1-LRR a
and EGFR1–501-Fc was loaded on to a Superdex 200 gel-fi
proteins. No complex was detected. y-Axis indicates absorbandowns from A431 or HEK293 cells overexpressing
both proteins nor could we detect an inhibitory effect
of LRIG1 on ligand-induced EGFR signalling.
Reports on the actions of LRIG1 range from direct
binding to the EGFR [9] to modulation of cell-surface
levels by inducing degradation and by inhibitingnd EGFR1–501-Fc. A mixture of FLAG-tagged LRIG1-LRR
ltration column and the fractions were analysed for both
ce unit (mAU) at 280 nm.
Fig. 9. Biosensor analysis of LRIG1-LRR-1Ig fragments and the EGFR-ECD. Various concentrations of LRIG1-LR-
R-1Ig fragment (from 8 μM to 0.25 μM in 2-fold dilutions) (a and c) and EGF (from 200 nM to 3.13 nM in 2-fold dilutions) (b
and d) were injected over immobilised EGFR1–621 (a and b) and EGFR1–501 (c and d). The calculated KD values for EGF
binding to EGFR1–621 and EGFR1–501 were 140 nM and 8 nM, respectively. The results shown are representative of two
experiments.
1943LRIG1: Structure and Function Analysistranscription and to direct interactions with ErbB2,
ErbB3, c-Met [9], and c-Ret [12]. LRIG1 has been
reported to promote cell–cell adhesion [12]. A
significant physiological action has been proposed
for LRIG1 in intestinal stem cells; that is, LRIG1
suppresses the activity of the EGFR [2,21]. In
cancers, the decrease in LRIG1 levels has been
proposed as a direct stimulus for cancer stem cell
self-renewal and proliferation [6,9,21,37–39]. How-
ever, in other cancers, LRIG1 is overexpressed
without any clear tumour suppressor effects [40].
Although the LRIG1 protein in our structure
function studies was expressed in insect cells and
thus may have a different glycosylation pattern, our
failure to detect any direct or indirect interaction
between LRIG1 and the EGFR expressed in human
cells suggests that our results with LRIG1-LRR,
LRIG1-LRR-1Ig, and LRIG1-3Ig in solution are not
simply due to over glycosylation.
It is important to establish definitively the roles of
LRIG1 in epithelial stem cells [2] and whether it has a
direct role in tumour suppression. A recent paper has
reported opposing effects of LRIG1 and LRIG3 on
the turnover of the EGFR and ErbB2 [17]. Indeed,
Rafidi's report suggests that LRIG1 can induce thedegradation of LRIG3 and thus decrease the
cell-surface levels of ErbB3 [17].
Since our structural results indicate that our
LRIG1-ECD is correctly folded, we expected to detect
the interactionwith the EGFRon the cell surface. All of
the previous studies used cell lines and systems
where either the LRIG1 or the HER family members
are overexpressed as recombinant proteins. It is
important that physiological systems and reagents
that will allow the analysis of the effects of LRIG1
expression, turnover, or modification in stem cell
populations are developed. Initial reports on trans-
genic mice where LRIG1 has been knocked out
indicate that the presence of LRIG1 leads to lower
levels of the EGFR and EGFR-associated tyrosine
phosphorylation [4]. In mice where LRIG1 has been
knocked out, there are significant increases in the
levels of EGFR familymembers in the basal crypt cells
[4]; however, the changes in EGFR phosphorylation
are less dramatic. Similarly, the effects on cell
production within a crypt appear to be modest. In
LRIG1−/−mice, the villus cell populations appear to be
normal, but there seems to be increased cell numbers
and turnover in the small intestinal crypts. The overall
cellularity of colon crypts in mice appears to be less
1944 LRIG1: Structure and Function AnalysisperturbedwhenLRIG1 is knocked out. Interestingly, in
some strains of mice, there is a 50% increase in the
circumference of the intestines when LRIG1 is
knocked out [4]; this increase in circumference
corresponds closely to the increase in the width of
the crypt base when LRIG1 is lost. However, in a
similar experiment where LRIG1 is knocked out in
mice with a different genetic background, no signifi-
cant change in the size of the colon was detected [41].
It is interesting to note that although Wong et al.
observed that the LRIG1−/− intestinal crypt morphol-
ogy could return to normal when the mice were
crossed on to a wa-2 background (i.e., the EGFRwas
kinase defective) [4], only a proportion of the crypts
reverted.
The most convincing report on the influence of
LRIG1-ECD on the activity of the EGFR family comes
fromdataonHeLacells, A431cells, andMDA-468cells
[9]. Purified LRIG1-ECD or LRIG1-ECD secreted by
HEK293 cells inhibited the proliferation of A431, HeLa,
and MDA-468 cells (1.5- to 3-fold after 3–6 days in
culture). A decorin-glycosylated fusion analogue of
LRIG1-ECD was more potent than wild-type LRI-
G1-ECD, but both proteins appeared to inhibit cell
proliferation. Furthermore, LRIG1-ECD inhibited the
proliferation of CHO-K1 cells expressing the EGFR (by
50% after 2 days), but not wild-type CHO-K1 cells. The
binding affinity of the LRIG1-ECD to A431 cells
(~10 nM) correlated well with the IC50 for inhibition of
Y1068 phosphorylation in the same cells; however, the
inhibitory effect of the LRIG1-ECD on EGF-stimulated
EGFR phosphorylation or Erk1/2 activation was less
potent.
Despite producing and purifying appropriately
folded LRIG-ECD fragments, our results are in
contrast to the data reported by Goldoni et al. [9], as
wecould not detect direct binding of the LRIG1-LRR to
the sEGFR-ECD or EGFR on the cell surface.
Similarly, Johansson et al. observed an anti-prolifer-
ative effect of LRIG1, whether or not glioma cells
expressed the EGFR [10]. Nor could we detect
an effect of soluble, purified LRIG1-ECD, or co-
expressed, full-length LRIG1 on the levels of EGFR,
the phosphorylation of the EGFR kinase, or on the
activation of EGFR signalling. Particularly worrying
are our results and the results of others [10]
indicating that the low level of binding of soluble
LRIG1-LRR-1Ig to cells is not dependent of the
cell-surface levels of the EGFR, suggesting that
other cell-surface interactions may lead to inter-
actions that interfere with our ability to conclude
that LRIG1 is a physiological regulator of the
EGFR family. Before we can conclude that LRIG1
is a functional or pan-ErbB inhibitor, the effects of
LRIG1 on EGFR; ErbB2, ErbB3, and/or ErbB4
levels; phosphorylation; and signalling need to be
measured by comparing epithelial stem cells with
wild-type levels of LRIG1 with the same cells
where LRIG1 has been deleted [42].Materials and Methods
Expression and purification of proteins
Synthetic DNAs (GenScript) corresponding to human
LRIG1-LRR (residues 41–494, AB050468) and LRIG1-3Ig
(residues 494–781) were cloned into the modified vector
[43]. Each construct contained a C-terminal TEV cleavage
site [44] followed by the FLAG-tagged sequence [45]. To
achieve high-level expression of LRIG1-LRR, we omitted
the signal sequence and placed four residues (42–44 and
69) at the N-terminus; that is, C41AAACTCAGDSLDCGG
RGLAALPGDLPSW was replaced with C41PSRCTCA
GDSLDCGGRGLAALPGDLPSS. These fragments of
the LRIG1-LRR and LRIG1-3Ig ectodomains were
expressed in Hi5 insect cells and purified by anti-FLAG
M2 beads (Sigma-Aldrich). The proteins were further
purified by gel filtration in 20 mM Tris–HCl (pH 8.5) and
100 mM NaCl.
The cloning, expression, and purification of FLAG-
tagged LRIG1-LRR-1Ig, FLAG-tagged EGFR1–501 and
FLAG-tagged EGFR1–621 were similar to that of the
LRIG1-LRR and LRIG1-3Ig fragments as described
above. Briefly, synthetic DNAs (Genescript) corresponding
to human LRIG1-LRR-1Ig (residues 41–596), EGFR1–501
(residues 1–501), and EGFR1–621 (residues 1–621) were
cloned into the modified vector and expressed in Hi5 insect
cells and purified by anti-FLAG M2 beads (Sigma-Aldrich).
The proteins were further purified by gel-filtration chroma-
tography on a pre-packed Superdex 200 column (GE
Healthcare) in 20 mM Hepes (pH 7.4), 150 mM NaCl, and
3 mM EDTA (ethylenediaminetetraacetic acid).
Crystallisation and data collection
A crystallisation screen was performed at the Collabo-
rative Crystallisation Centre, CSIRO, Parkville. Although
high-quality crystals for LRIG1-LRR were grown at 18%
PEG (polyethylene glycol) 4000 and 0.1 M Hepes
(pH 7.5), the best crystals of LRIG1-LRR, which diffracted
to 2.3 Å, were grown at 16% PEG 4000 and 0.1 M Hepes
(pH 7.0) with 10 mM Taurine by streaked seeding from
the initial conditions. LRIG1-3Ig crystals were grown from
0.8 M sodium succinate (pH 7.0) at 5 mg/mL. All X-ray
diffraction data were collected on the Australian Synchro-
tron microcrystal beamline MX2 [46]. The resultant data
sets were processed and scaled with the XDS package
[47]. The resolution cutoff was set on the basis of the
Karplus CC(1/2) parameter [48]. The crystal statistics are
summarised in Table 1.
Structure determination and refinement
The crystal of LRIG1-LRR belongs to space group
P212121 with one molecule in the asymmetric unit. Data at
a resolution of 2.3 Å were used to perform molecular
replacement calculations using PHASER [49]. A search
model was generated from the coordinates of decorin
(PDB entry 1XKU [24]) that were modified by changing all
non-identical residues to serine using the online server
FFAS03§. One top solution was found in the asymmetric
unit with the Z-scores and log-likelihood gain: RFZ = 4.2,
1945LRIG1: Structure and Function AnalysisTFZ = 9.4, and LLG = 127. The resulting model had
reasonable packing although it did not refine to an
acceptable R-factor. Subsequently PHENIX [50] automat-
ed building and morphing routines were used to produce a
model that comprised 274 residues from 454 residues.
Further rounds of refinement and manual rebuilding were
undertaken using PHENIX [50] and Coot [51]. Statistics for
the final model are listed in Table 1.
The crystal of LRIG1-3Ig belongs to space group P43
212. A search model was produced in the same way
as the LRIG1-LRR model by using FFAS03 from the
structure of the Titin I1 domain (PDB code 1G1C [52]).
PHASER found two of the three Ig domains. This initial
model was refined with PHENIX [50] and manual
rebuilding was undertaken using Coot [51]. These two
domains corresponded to the second and third Ig
domains of LRIG1-3Ig. The first Ig domain was manually
built into the model by using the coordinates of LRIG3-Ig1
structure (PDB code 3SO5).Immunofluorescence staining
SW480 and SW620 cells (5 × 103/well) were preincu-
bated in Ibidi chamber slides (Ibidi, Germany) for 3 days
then stimulated with or without EGF (100 ng/mL) at 37 °C
for 15 min. After washing with PBS (phosphate-buffered
saline), we incubated the cells with or without FLAG-L-
RIG1-LRR-1Ig (1 μM) at 4 °C for 45 min. The cells were
washed with PBS and stained with the mouse anti-EGFR
antibody 528 [53] or with the mouse anti-FLAG antibody
(Sigma-Aldrich; cat. no. A2220) to detect the FLAG-L-
RIG1-LRR followed by staining with Alexa 488-labelled
anti-mouse Ig (Invitrogen; cat. no. A11001). Both bright
field and fluorescence images were captured.
Cell culture, reagents, and antibodies
The human embryonic kidney cell line 293T HEK293T
and the human epidermoid carcinoma cell line A431 that
expresses high levels of the epidermal growth factor (EGF)
receptor were maintained in Dulbecco's modified Eagle's
medium (DMEM) containing 10% bovine calf serum (BCS)
(HyClone) at 37 °C in a 10% CO2 incubator. Full-length
human LRIG1 cDNA construct was purchased from
OriGene (cat. no. RC223584), which contains a C-terminal
Myc-DDK tag that allows detection by both the anti-Myc
and the anti-FLAG antibodies. X-tremeGENE HP DNA
transfection reagent and complete protease inhibitor
EDTA-free mixture tablets were obtained from Roche
Diagnostics. Anti-FLAG-M2-agarose resin was from Sig-
ma-Aldrich. Bovine serum albumin (BSA) fraction V and
NuPAGE precast gels were from Life Technologies.
PVDF-Plus membrane was from GE Water & Process
Technologies. Protein G-Sepharose resin, Amersham
ECL kit, ECL film, and donkey anti-rabbit-Ig-HRP and
sheep anti-mouse-Ig-HRP were from GE Healthcare. ECL
Luminata Forte reagent and mouse anti-phosphotyrosine
mAb (monoclonal antibody), clone 4G10 (cat. no. 05-321),
were from Millipore. Mouse anti-EGFR mAb 806 was
produced at the Antibody Production Facility of the Ludwig
Institute for Cancer Research, Heidelberg. Rabbit anti-
Erk1/2 antibody (cat. no. 9101) was from Cell Signaling
Technology. Rat anti-FLAG mAb (clone 9H1) and mouseanti-Myc mAb (clone 9E10) were from the WEHI Antibody
Facility.EGFR phosphorylation inhibition assay
Two days before the assay, A431 cells were seeded
in two 6-well plates at 0.5 × 106 cells/well (plate 1) and
0.15 × 106 cells/well (plate 2), respectively. When cells
reached confluence, culture medium in plate 1 was
removed and 1.5 mL of either recombinant LRIG1-LRR
or LRIG1-3Ig was added to wells at 0, 10, and 100 μg/mL,
respectively, in DMEM/10% (vol/vol) BCS. For plate 2,
culture medium was removed and cells in each well were
rinsed once with 3 mL of DMEM containing 0.1% BSA
once and then 1.5 mL of either recombinant LRIG1-LRR
or LRIG1-3Ig was added to wells also at 0, 10, and 100 μg/
mL, respectively. Cells were incubated at 37 °C for a further
2 h in DMEM/0.2% BSA fraction V. The medium was
removed and cells were washed once with 3 mL of ice-cold
mouse-tonicity PBS and lysed in plates with 150 μL of lysis
buffer containing 1% (vol/vol) Triton X-100, 50 mMTris–HCl
(pH 7.5), 150 mM NaCl, and 1 mM EDTA, freshly supple-
mented with 2 mM Na3VO4, 10 mMNaF, 1 mMPMSF, and
complete protease inhibitor mixture. Protein extracts were
separated by SDS-PAGE, followed by Western blot
analysis.Transient transfection and expression of full-length
FLAG-Myc-tagged LRIG1 in A431 cells
One day before transfection, A431 cells were seeded in
T150 flasks at 8 × 106 cells/flask in 40 mL of DMEM/10%
BCS. Cells in parallel flasks were transfected with 10 μg of
full-length FLAG-tagged LRIG1 cDNA construct from
OriGene or an empty vector using X-tremeGENE HP
DNA transfection reagent according to the manufacturer's
instructions. At 48 h posttransfection, medium was re-
moved and cells were rinsed twice with 50 mL of ice-cold
normal saline and lysed on ice for 1 h in NP-40 lysis buffer
containing 1% (vol/vol) NP-40, 10% (vol/vol) glycerol,
2 mM Na3VO4, 10 mM NaF, 1 mM PMSF, and complete
protease inhibitor EDTA-free mixture in 50 mM Tris–HCl
(pH 7.4) and 150 mM NaCl. Whole cell lysates were
cleared by centrifugation at 16,000g for 15 min at 4 °C,
followed by immunoprecipitation with 50 μL of anti-FLAG
M2-agarose beads for 2 h at 4 °C on a rotating wheel. The
M2 beads were washed, washed first with 10 mL cold
normal saline then three times with 5 mL of NP-40 lysis
buffer. Bound proteins were first eluted at 4 °C for 10 min
with 400 μL of 1 mg/mL FLAG peptide, followed by a
second elution with 400 μL of 0.5% SDS. Eluted proteins
and residual beads were separated by SDS-PAGE,
followed by Western blot analysis.Transient transfection of full-length FLAG-Myc-tagged
LRIG1 and FLAG-tagged EGFR in HEK293 cells
To examine the interaction between LRIG1 and EGFR,
we transfected HEK293T cells with full-length LRIG1
cDNA construct from OriGene, full-length EGFR cDNA
construct, or a combination of these two constructs.
1946 LRIG1: Structure and Function AnalysisTransfection and cell lysis were performed identically as
described for A431 cells. Co-immunoprecipitation was
performed using 6 μg of anti-Myc mAb 9E10 and 20 μL of
protein G-Sepharose beads for 2 h at 4 °C on a wheel. The
protein G beads were washed three times each with 1 mL
of lysis buffer and bound proteins (immunoprecipitates)
eluted from the beads with Laemmli-reducing SDS sample
buffer. Immunoprecipitates were separated by SDS-PAGE,
followed by Western blot analysis.
Analysis of LRIG1-LRR interaction with EGFR1–621 and
EGFR1–501-Fc [54] by gel-filtration chromatography
We mixed 190 μg of EGFR1–501-Fc [36] with 120 μg of
LRIG1-LRR in a volume of 500 μL and concentrated them
to 50 μL using Amicon centrifugal filter unit (Merck
Millipore). The protein mixture was incubated on ice for
2 h and loaded onto a pre-packed Superdex 200 column
(300 × 10 mm from GE Healthcare) equilibrated in 25 mM
Hepes (pH 7.4) containing 100 mM NaCl and chromato-
graphed at a flow rate of 0.5 mL/min. Aliquots (20 μL) of
column fractions (0.5 mL) were analysed by SDS-PAGE
and Coomassie blue staining.Biosensor analysis: Interaction analysis using
surface plasmon resonance
Protein–protein interaction was analysed using a Bia-
core 3000 biosensor. EGFR proteins were immobilised to
a CM5 chip by amine coupling according to the manufac-
turer's instructions to between 2000 and 4000 RU.
LRIG1-LRR-1Ig and LRIG1-3Ig fragments and EGF were
diluted in 10 mM Hepes, 150 mM NaCl, 3 mM EDTA, and
0.005% Tween 20 (pH 7.4) and were injected over the flow
cells at 10 μL/min for 12 min, followed by dissociation for
23 min. The surfaces were regenerated with 50 μL of
10 mM glycine–HCl (pH 2.5) at 50 μL/min. Bulk effects
were subtracted using a blank flow cell and rate constants
were calculated using BIAevaluation software.Accession numbers
Accession numbers are as follows: 4U7L for LRR and
4U7M for 3Ig.
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